

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



天大藥業有限公司

TIANDA PHARMACEUTICALS LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 00455)

PROFIT WARNING

This announcement is made by Tianda Pharmaceuticals Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) wishes to inform the shareholders of the Company and potential investors that, based on the preliminary assessments on the Group’s unaudited consolidated management accounts for the year ended 31 December 2024 (the “**Current Financial Year**”), it is expected that the loss attributable to shareholders of the Company for the Current Financial Year would be increased to not less than HK\$61 million as compared to that of HK\$24.2 million for the year ended 31 December 2023 (“**Previous Financial Year**”). The increase in loss attributable to shareholders of the Company was mainly due to the following: (1) the Group’s revenue for the Current Financial Year decreased by approximately 38% as compared to the Previous Financial Year; and (2) an impairment of goodwill of HK\$1.3 million is provided in the Current Financial Year (such impairment is non-recurring, non-cash in nature and will not have any cash flow impact to the Group).

The Group is still in the process of finalising the audited consolidated annual results for the Current Financial Year. Hence, the information contained in this announcement is based on a preliminary assessment by the Board and the management of the Group based on the latest information currently available to the Board, which has not been audited or reviewed by the independent auditors of the Company or the audit committee of the Company. As such, the results for the Current Financial Year may be different from what is disclosed in this announcement.

The Board expects that the announcement of the annual results of the Group will be published on 28 March 2025 in compliance with the requirements under the Listing Rules.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

For and on behalf of the Board
Tianda Pharmaceuticals Limited
FANG Wen Quan
Chairman and Managing Director

Hong Kong, 25 March, 2025

As at the date of this announcement, the executive Directors are Mr. FANG Wen Quan (Chairman and Managing Director) and Mr. LUI Man Sang; the non-executive Directors are Mr. ZHONG Tao and Mr. FENG Quanming; and the independent non-executive Directors are Mr. LAM Yat Fai, Mr. CHIU Sung Hong and Dr. XIAN Yanfang.